Sfoglia per AUTORE
LI Q
Collezione AOU Novara

  

Items : 4

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial. in Nature medicine / Nat Med. 2025 May;31(5):1531-1538. doi: 10.1038/s41591-025-03572-3. Epub 2025 Mar 10.
2025
AOU Novara

Rampal RK; Grosicki S; Chraniuk D; Abruzzese E; Bose P; Gerds AT; Vannucchi AM; Palandri F; Lee SE; Gupta V; Lucchesi A; Oh ST; Kuykendall AT; Patriarca A; Álvarez-Larrán A; Mesa R; Kiladjian JJ; Talpaz M; Scandura JM; Lavie D; Harris M; Kays SK; Li Q; Boxhammer R; Brown B; Jegg AM; Harrison CN; Mascarenhas J;

A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease. in Hepatology international / Hepatol Int. 2024 Aug;18(4):1178-1201. doi: 10.1007/s12072-024-10702-5. Epub 2024 Jun 15.
2024
AOU Novara

Zhang H; Targher G; Byrne CD; Kim SU; Wong VW; Valenti L; Glickman M; Ponce J; Mantzoros CS; Crespo J; Gronbaek H; Yang W; Eslam M; Wong RJ; Machado MV; Yu ML; Ghanem OM; Okanoue T; Liu JF; Lee YH; Xu XY; Pan Q; Sui M; Lonardo A; Yilmaz Y; Zhu LY; Moreno C; Miele L; Lupsor-Platon M; et alii...

Significant response from fruquintinib plus anti-PD-1 immunotherapy for microsatellite stable metastatic colorectal cancer with liver and lung metastasis in the third line: case report. in Journal of gastrointestinal oncology / J Gastrointest Oncol. 2023 Dec 31;14(6):2617-2626. doi: 10.21037/jgo-23-862. Epub 2023 Dec 27.
2023
AOU Novara

He L; Cheng X; Zhou C; Li Q; Zhang B; Cheng X; Donadon M; Mannavola F; Tu S;

2021
AOU Novara

Klionsky DJ; Abdel-Aziz AK; Abdelfatah S; Abdellatif M; Abdoli A; Abel S; Abeliovich H; Abildgaard MH; Abudu YP; Acevedo-Arozena A; Adamopoulos IE; Adeli K; Adolph TE; Adornetto A; Aflaki E; Agam G; Agarwal A; Aggarwal BB; Agnello M; Agostinis P; Agrewala JN; Agrotis A; Aguilar PV; Ahmad ST; Ahmed ZM; Ahumada-Castro U; Aits S; Aizawa S; Akkoc Y; et alii...